基本信息:
- 专利标题： QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS
- 申请号：PCT/EP2020/085460 申请日：2020-12-10
- 公开(公告)号：WO2021116260A1 公开(公告)日：2021-06-17
- 发明人： AMARI, Gabriele , ARMANI, Elisabetta , PAGANO, Mafalda , GIULIANI, Marta , RAVEGLIA, Luca , BEATO, Claudia
- 申请人： CHIESI FARMACEUTICI S.P.A.
- 申请人地址： Via Palermo 26/A
- 专利权人： CHIESI FARMACEUTICI S.P.A.
- 当前专利权人： CHIESI FARMACEUTICI S.P.A.
- 当前专利权人地址： Via Palermo 26/A
- 优先权： EP19215719.6 2019-12-12
- 主分类号： A61P1/16
- IPC分类号： A61P1/16 ; A61P9/00 ; A61P11/00 ; A61P27/02 ; C07D401/12 ; C07D407/14 ; C07D409/14 ; C07D413/14 ; C07D417/14 ; A61K31/517
摘要：
The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
IPC结构图谱:
| A | 人类生活必需 |
| --A61 | 医学或兽医学；卫生学 |
| ----A61P | 化合物或药物制剂的治疗活性 |
| ------A61P1/00 | 治疗消化道或消化系统疾病的药物 |
| --------A61P1/16 | .治疗肝脏或胆囊疾病的药物，例如保肝药、利胆药、溶石药 |